Return to site

Salspera Announces Poster Presentation at the American Association for Cancer Research 2021 Annual Meeting

OAKDALE, Mar. 11th, 2021 - Salspera, LLC, a clinical-stage biopharmaceutical company dedicated to the development of microbial based immunotherapies, today announced that it will present a poster at the American Association for Cancer Research (AACR) Annual Meeting, to be held in a virtual format from April 10th to 15th and May 17th to 21st, 2021.

Title: Microbial based immunotherapy: Saltikva as a novel therapeutic for solid tumors

Session Title: Immunomodulatory Agents and Interventions

Session Category: Immunology

Abstract Number: 5052, e-poster

Date and Time: Saturday, April 10, 2021, 8:30 a.m. ET via the AACR website, www.aacr.org

About Salspera

Salspera is a private, clinical stage biotech company developing its platform of orally administered microbiome immunotherapies in solid tumors. The deep pipeline consists of orally administered microbiome immunotherapies, genetically engineered to eliminate pathogenicity and express various cytokines and cytotoxic proteins within the tumor microenvironment. The lead asset, Saltikva, is currently in an on-going phase 2 clinical study in Stage 4 metastatic pancreatic cancer patients in Canada. It is also being developed in additional solid tumors with the plan to initiate further phase 2 studies. The platform consists of numerous constructs engineered to deliver among others, PD-L1, CTLA-4, IL-15 intra-tumorally. These are currently undergoing IND enabling studies with plans to move them to the clinic.

For more information, please visit 

salspera.com.

Salspera Contact

Chandler Glass

VP of Business Development

cglass@salspera.com

Keywords: Saltikva, cancer, oncology, immune, therapy, immunotherapy, bacterial based cancer therapy, microbial immunotherapy, chemotherapy, pancreatic cancer, tumor microenvironment, immuno oncology, interleukin-2, cytokine, bacteria, Salspera

All Posts
×

Almost done…

We just sent you an email. Please click the link in the email to confirm your subscription!

OK